Organization
Queen Mary Hospital
4 clinical trials
12 abstracts
Abstract
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.Org: University Medical Center Mainz, University Grenoble Alpes, CHU Grenoble Alpes, Institute for Advanced Biosciences, Kindai University Faculty of Medicine, Osaka-Sayama, Japan,
Abstract
The TAC-GReD trial: The combination of talazoparib and carboplatin in DNA damage repair deficient recurrent high-grade glioma.Org: Department of Clinical Oncology, Queen Elizabeth Hospital, LKS Faculty of Medicine, University of Hong Kong, Department of Neurosurgery, Prince of Wales Hospital, Prince of Wales Hospital,
Clinical trial
A Double-Blind Randomized Controlled Trial of N-acetylcysteine (NAC) for the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseStatus: Recruiting, Estimated PCD: 2025-09-30
Abstract
Utility of an amplicon-based ctDNA platform for advanced cholangiocarcinomas (CCA) in asia.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, The University of Hong Kong, Queen Mary Hospital, Lucence Diagnostics Pte Ltd,
Clinical trial
Efficacy and Safety of add-on Topical Timolol in the Management of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-induced Paronychia: A Prospective Randomized Open-labelled TrialStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Randomized Double Blind Controlled Trial of Non-invasive Preimplantation Genetic Testing for Aneuploidy in Women With Recurrent Pregnancy LossStatus: Not yet recruiting, Estimated PCD: 2025-02-27
Clinical trial
Randomized Controlled Trial on Use of Letrozole in the Medical Management of Tubal Ectopic PregnanciesStatus: Recruiting, Estimated PCD: 2024-12-30
Abstract
A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.Org: Cairns and Hinterland Hospital and Health Service, Cancer Research South Australia (CRSA), Queen Mary Hospital, Gilead Sciences, Inc., Gilead Sciences Inc,
Abstract
Preliminary results of sequential transarterial chemoembolization and stereotactic body radiotherapy followed by immunotherapy using single tremelimumab regular interval durvalumab in locally advanced, unresectable hepatocellular carcinoma (START-FIT using STRIDE): A single-arm, phase II study.Org: The University of Hong Kong, The Chinese University of Hong Kong, Department of Clinical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Tuen Mun Hospital, University of Hong Kong,
Abstract
Autologous cytotoxic T-cell receptor T cell therapy (SCG101) against hepatitis B surface antigen phase I/II trial for patients with advanced hepatitis B-related hepatocellular carcinoma.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, Cornell University, National University Hospital, Department of Clinical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University,
Abstract
VELOCITY-Lung: A phase (Ph) 2 study evaluating safety and efficacy of domvanalimab (dom) + zimberelimab (zim) + sacituzumab govitecan (SG), or etrumadenant (etruma) + dom + zim, or etruma + zim in patients (pts) with treatment-naïve metastatic non-small cell lung cancer (mNSCLC).Org: Virginia Cancer Specialists, Queen Mary Hospital, Chang Gung Medical Foundation-LinKou Branch, Rambam Health Care, St Barthlomew's Hospital,
Abstract
Peripheral immunological response to treatment with a novel bifunctional anti-PD-L1/TGFβRII agent in recurrent/metastatic nasopharyngeal carcinoma.Org: Laboratory for Synthetic Chemistry and Chemical Biology, InnoHK, Hong Kong, China, The University of Hong Kong, Hong Kong, Department of Clinical Oncology, University of Hong Kong, Hongkong, China, Department of Clinical Oncology, The University of Hong Kong, Hong Kong, Laboratory of Synthetic Chemistry and Chemical Biology Limited, Hong Kong,
Abstract
A case-control study of 10,757 individuals to assess potentially modifiable risk factors, including stress, for breast cancer among Chinese patients in Hong Kong.Org: The Chinese University of Hong Kong, Hong Kong Breast Cancer Foundation, Princess Margaret Hospital, Pamela Youde Nethersole Eastern Hospital, Tuen Mun Hospital,
Abstract
A MULTIPLE DOSE STUDY OF AMG 811 (ANTI-IFN-GAMMA) IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND ACTIVE NEPHRITIS Org: Amgen, Mount Sinai Hospital, University Malaya Medical Centre, Queen Mary Hospital, Hospital Pitié-Salpètrière,
Abstract
ANTI-TNF DRUGS AND CARDIOVASCULAR EVENTS IN PATIENTS WITH SPONDYLOARTHRITISOrg: The University of Hong Kong, Queen Mary Hospital, Division of Rheumatology and Clinical Immunology, School of Medicine, Keio University, Department of Medicine, University of Alberta, Alberta, Canada,
Abstract
ANTIPHOSPHOLIPID ANTIBODY PROFILES IN CHINESE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSOrg: Department of Medicine, University of Alberta, Alberta, Canada, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Queen Mary Hospital, Hong Kong Sanatorium & Hospital, Hong Kong Special Administrative,